HCA Healthcare Q4 net income rises 30.6%; sets 2026 EPS guidance at $29.10-$31.50
HCA Healthcare reported fourth-quarter 2025 revenue of $19.513 billion, up 6.7 percent, and diluted EPS of $8.14, up 44.6 percent from a year earlier, when results included a $0.59 per share facility loss. The company also issued 2026 guidance of $29.10 to $31.50 diluted EPS and authorized an additional $10 billion share repurchase program, with a $0.78 quarterly dividend declared.
Key points
- Q4 2025 net income attributable to HCA was $1.878 billion, up 30.6 percent; adjusted diluted EPS was $8.01, up 28.8 percent.
- Full-year 2025 revenue was $75.600 billion and diluted EPS was $28.33, compared with $22.00 in 2024.
- 2026 guidance: revenue $76.500 to $80.000 billion; net income $6.495 to $7.035 billion; adjusted EBITDA $15.550 to $16.450 billion.
- Board authorized up to $10 billion in additional buybacks and declared a $0.78 dividend payable March 31, 2026.
The filing
Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 27, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.